Prognostic Value of Plasma Trimethylamine N-Oxide Levels in Patients with Acute Ischemic Stroke
Tóm tắt
Trimethylamine N-oxide (TMAO) has emerged as a newly identified gut microbiota-dependent metabolite contributing to a variety of diseases, such as diabetes, atherosclerosis, and cardiovascular diseases. The aim of our study was to determine whether a relatively high TMAO level is associated with an increased risk of poor outcome in ischemic stroke patients. From June 2018 to December 2018, we prospectively recruited acute ischemic stroke patients diagnosed within 24 h of symptom onset. The plasma TMAO level was measured at admission for all patients. Functional outcome was evaluated at 3 months after the stroke using the modified Rankin Scale (mRS) and then dichotomized as favorable (mRS 0–2) or unfavorable (mRS 3–6). A multivariate logistic regression analysis was conducted to evaluate the association between TMAO concentration and poor functional outcome and mortality at 3 months. Of the 225 acute ischemic stroke patients included in the analysis, the median TMAO concentration was 3.8 µM (interquartile range, 1.9–4.8 µM). At 3 months after admission, poor functional outcome was observed in 116 patients (51.6%), and 51 patients had died (22.7%). After adjusting for potential confounders, patients with TMAO levels in the highest quartile were more likely to have higher risks of poor functional outcome [compared with the lowest quartile, odds ratio (OR) 3.63; 95% confidence interval (CI) 1.34–9.82; P = 0.011] and mortality (OR 4.27; 95% CI 1.07–17.07; P = 0.040). Our data suggest that a high plasma TMAO level upon admission may predict unfavorable clinical outcomes in acute ischemic stroke patients.
Tài liệu tham khảo
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35–41
Angiolillo D, Bernardo E, Sabaté M, Jimenez-Quevedo P, Costa M, Palazuelos J, Hernández-Antolin R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Guzman L, Bass T, Macaya C, Fernandez-Ortiz A (2007) Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 50:1541–1547
Bennett B, de Aguiar Vallim T, Wang Z, Shih D, Meng Y, Gregory J, Allayee H, Lee R, Graham M, Crooke R, Edwards P, Hazen S, Lusis A (2013) Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab 17:49–60
Boini K, Hussain T, Li P, Koka S (2017) Trimethylamine-N-oxide instigates NLRP3 inflammasome activation and endothelial dysfunction. Cell Physiol Biochem 44:152–162
Bonita R, Mendis S, Truelsen T, Bogousslavsky J, Toole J, Yatsu F (2004) The global stroke initiative. Lancet Neurol 3:391–393
Chen M, Zhu X, Ran L, Lang H, Yi L, Mi M (2017) Trimethylamine-N-oxide induces vascular inflammation by activating the NLRP3 inflammasome through the SIRT3-SOD2-mtROS signaling pathway. J Am Heart Assoc 6:e006347
Clemente J, Ursell L, Parfrey L, Knight R (2012) The impact of the gut microbiota on human health: an integrative view. Cell 148:1258–1270
Craciun S, Balskus E (2012) Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. Proc Natl Acad Sci USA 109:21307–21312
de Margerie-Mellon C, Turc G, Tisserand M, Naggara O, Calvet D, Legrand L, Meder JF, Mas JL, Baron JC, Oppenheim C (2013) Can DWI-ASPECTS substitute for lesion volume in acute stroke? Stroke 44:3565–3567
Dinan T, Cryan J (2017) Gut instincts: microbiota as a key regulator of brain development, ageing and neurodegeneration. J Physiol 595:489–503
Duan Z, Wang H, Wang Z, Hao Y, Zi W, Yang D, Zhou Z, Liu W, Lin M, Shi Z, Lv P, Wan Y, Xu G, Xiong Y, Zhu W, Liu X (2018) Neutrophil-lymphocyte ratio predicts functional and safety outcomes after endovascular treatment for acute ischemic stroke. Cerebrovasc Dis 45:221–227
Goldstein L, Samsa G (1997) Reliability of the National Institutes of Health Stroke Scale. Extension to non-neurologists in the context of a clinical trial. Stroke 28:307–310
Haghikia A, Li X, Liman T, Bledau N, Schmidt D, Zimmermann F, Kränkel N, Widera C, Sonnenschein K, Haghikia A, Weissenborn K, Fraccarollo D, Heimesaat M, Bauersachs J, Wang Z, Zhu W, Bavendiek U, Hazen S, Endres M, Landmesser U (2018) Gut Microbiota-dependent trimethylamine N-oxide predicts risk of cardiovascular events in patients with stroke and is related to proinflammatory monocytes. Arterioscler Thromb Vasc Biol 38:2225–2235
Li D, Ke Y, Zhan R, Liu C, Zhao M, Zeng A, Shi X, Ji L, Cheng S, Pan B, Zheng L, Hong H (2018) Trimethylamine-N-oxide promotes brain aging and cognitive impairment in mice. Aging Cell 17:e12768
Liu M, Wu B, Wang W, Lee L, Zhang S, Kong L (2007) Stroke in China: epidemiology, prevention, and management strategies. Lancet Neurol 6:456–464
Liu L, Wang D, Wong K, Wang Y (2011) Stroke and stroke care in China: huge burden, significant workload, and a national priority. Stroke 42:3651–3654
Nie J, Xie L, Zhao B, Li Y, Qiu B, Zhu F, Li G, He M, Wang Y, Wang B, Liu S, Zhang H, Guo H, Cai Y, Huo Y, Hou F, Xu X, Qin X (2018) Serum trimethylamine N-oxide concentration is positively associated with first stroke in hypertensive patients. Stroke 49:2021–2028
Schiattarella G, Sannino A, Toscano E, Giugliano G, Gargiulo G, Franzone A, Trimarco B, Esposito G, Perrino C (2017) Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. Eur Heart J 38:2948–2956
Schwammenthal Y, Tsabari R, Shenkman B, Schwartz R, Matetzky S, Lubetsky A, Orion D, Israeli-Korn S, Chapman J, Savion N, Varon D, Tanne D (2008) Aspirin responsiveness in acute brain ischaemia: association with stroke severity and clinical outcome. Cerebrovasc Dis 25:355–361
Seldin M, Meng Y, Qi H, Zhu W, Wang Z, Hazen S, Lusis A, Shih D (2016) Trimethylamine N-oxide promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear factor-κB. J Am Heart Assoc 5:e002767
Siniscalchi A, Iannacchero R, Anticoli S, Pezzella F, De Sarro G, Gallelli L (2016) Anti-inflammatory strategies in stroke: a potential therapeutic target. Curr Vasc Pharmacol 14:98–105
Tang W, Wang Z, Levison B, Koeth R, Britt E, Fu X, Wu Y, Hazen S (2013) Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 368:1575–1584
Tóth N, Székely E, Czuriga-Kovács K, Sarkady F, Nagy O, Lánczi L, Berényi E, Fekete K, Fekete I, Csiba L, Bagoly Z (2018) Elevated Factor VIII and von Willebrand factor levels predict unfavorable outcome in stroke patients treated with intravenous thrombolysis. Front Neurol 8:721
Tremaroli V, Bäckhed F (2012) Functional interactions between the gut microbiota and host metabolism. Nature 489:242–249
Wang Q, Tang X, Yenari M (2007) The inflammatory response in stroke. J Neuroimmunol 184:53–68
Wang Z, Klipfell E, Bennett B, Koeth R, Levison B, Dugar B, Feldstein A, Britt E, Fu X, Chung Y, Wu Y, Schauer P, Smith J, Allayee H, Tang W, DiDonato J, Lusis A, Hazen S (2011) Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472:57–63
Wang Z, Levison B, Hazen J, Donahue L, Li X, Hazen S (2014) Measurement of trimethylamine-N-oxide by stable isotope dilution liquid chromatography tandem mass spectrometry. Anal Biochem 455:35–40
Wilson A, McLean C, Kim R (2016) Trimethylamine-N-oxide: a link between the gut microbiome, bile acid metabolism, and atherosclerosis. Curr Opin Lipidol 27:148–154
Wu C, Li C, Zhao W, Xie N, Yan F, Lian Y, Zhou L, Xu X, Liang Y, Wang L, Ren M (2018) Elevated trimethylamine N-oxide related to ischemic brain lesions after carotid artery stenting. Neurology 90:e1283–e1290
Yang C, Hawkins K, Doré S, Candelario-Jalil E (2019) Neuroinflammatory mechanisms of blood–brain barrier damage in ischemic stroke. Am J Physiol Cell Physiol 316:C135–C153
Zhu W, Gregory J, Org E, Buffa J, Gupta N, Wang Z, Li L, Fu X, Wu Y, Mehrabian M, Sartor R, McIntyre T, Silverstein R, Tang W, DiDonato J, Brown J, Lusis A, Hazen S (2016) Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell 165:111–124